(MLYS) Mineralys Therapeutics - Performance 6.8% in 12m
MLYS performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
0.04%
#33 in Peer-Group
Rel. Strength
50.72%
#3777 in Stock-Universe
Total Return 12m
6.78%
#57 in Peer-Group
Total Return 5y
-9.44%
#38 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | - |
| P/E Forward | - |
| High / Low | USD |
|---|---|
| 52 Week High | 16.87 USD |
| 52 Week Low | 8.76 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 54.94 |
| Buy/Sell Signal +-5 | -0.20 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: MLYS (6.8%) vs XBI (-11.1%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| GILD NASDAQ Gilead Sciences |
1.02% | 61.8% | 74.7% | 23.5 | 14.1 | 0.23 | 28.3% | -3.71% |
| UTHR NASDAQ United Therapeutics |
6.89% | -8.76% | 155% | 12 | 11 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
1.19% | -6.24% | 38% | 27.2 | 14.2 | 0.99 | 0.60% | 41% |
| BIM PA Biomerieux |
-2.29% | 26.9% | -2.56% | 32.7 | 25.8 | 1.55 | -38.5% | -25.1% |
| NBIX NASDAQ Neurocrine Biosciences |
7.48% | -8.9% | 5.85% | 45.7 | 26.2 | 0.27 | 18.7% | -34.3% |
| KMDA NASDAQ Kamada |
11.5% | 27.6% | -6.21% | 27.6 | 22.4 | 0.9 | 68.9% | 36.8% |
| PTCT NASDAQ PTC Therapeutics |
-4.47% | 46.2% | -8.05% | 7.54 | 6.09 | 0.81 | - | 68% |
| ERF PA Eurofins Scientific SE |
1.64% | 26.9% | 19% | 28.9 | 15.4 | 0.64 | -62.1% | -19.3% |
Performance Comparison: MLYS vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for MLYS
| Total Return (including Dividends) | MLYS | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -6.82% | 3.15% | 4.01% |
| 3 Months | 8.13% | 17.08% | 17.14% |
| 12 Months | 6.78% | -11.14% | 13.46% |
| 5 Years | -9.44% | -21.96% | 112.73% |
| Trend Score (consistency of price movement) | MLYS | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 7.7% | 52.1% | 90.3% |
| 3 Months | 14.1% | 79.4% | 97.5% |
| 12 Months | 42.7% | -87.4% | 46.4% |
| 5 Years | -11.6% | -52.1% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | %th31.50 | -9.66% | -10.41% |
| 3 Month | %th33.50 | -7.64% | -7.69% |
| 12 Month | %th72.00 | 20.17% | -5.89% |
| 5 Years | %th76.50 | -10.56% | -42.85% |
FAQs
Does Mineralys Therapeutics (MLYS) outperform the market?
Yes,
over the last 12 months MLYS made 6.78%, while its related Sector, the SPDR S&P Biotech (XBI) made -11.14%.
Over the last 3 months MLYS made 8.13%, while XBI made 17.08%.
Performance Comparison MLYS vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
MLYS vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 6.6% | -10.8% | 46.9% | -7% |
| US NASDAQ 100 | QQQ | 6.7% | -11% | 44.9% | -7% |
| German DAX 40 | DAX | 6.3% | -8% | 34.8% | -23% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 5.4% | -11.4% | 42.5% | -12% |
| Hongkong Hang Seng | HSI | 5.7% | -9.7% | 24.9% | -28% |
| India NIFTY 50 | INDA | 8% | -6% | 46.5% | 10% |
| Brasil Bovespa | EWZ | 10.8% | -6.2% | 31.9% | 5% |
MLYS vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 8% | -8.5% | 43.6% | -17% |
| Consumer Discretionary | XLY | 5.7% | -10.2% | 54.6% | -11% |
| Consumer Staples | XLP | 8.7% | -6.7% | 47.9% | -1% |
| Energy | XLE | 3.7% | -11% | 54.5% | 5% |
| Financial | XLF | 8.1% | -9.5% | 44.6% | -19% |
| Health Care | XLV | 6.5% | -6.9% | 58.4% | 13% |
| Industrial | XLI | 6.2% | -11.3% | 41.1% | -17% |
| Materials | XLB | 6% | -11.3% | 46.3% | 3% |
| Real Estate | XLRE | 6.9% | -6.7% | 48.4% | -1% |
| Technology | XLK | 6.7% | -13.5% | 41.8% | -4% |
| Utilities | XLU | 6.6% | -9.4% | 42.9% | -13% |
| Aerospace & Defense | XAR | 6% | -13.7% | 26.9% | -42% |
| Biotech | XBI | 3% | -10% | 57.2% | 18% |
| Homebuilder | XHB | 3.6% | -15.6% | 53.5% | 8% |
| Retail | XRT | 6.7% | -10.1% | 51.7% | 0% |
MLYS vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | 6% | -10.1% | 60.8% | 11% |
| Natural Gas | UNG | 8.4% | -0.4% | 72.9% | 9% |
| Gold | GLD | 6.5% | -7.1% | 29% | -32% |
| Silver | SLV | 2.3% | -13.1% | 24.9% | -15% |
| Copper | CPER | -3.7% | -21.8% | 27.4% | -17% |
MLYS vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | 7.5% | -6.8% | 52.2% | 11% |
| iShares High Yield Corp. Bond | HYG | 7.2% | -8% | 49.9% | -2% |